We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.
- Authors
Mocroft, A.; Reiss, P.; Rakhmanova, A.; Banhegyi, D.; Phillips, A.; Wit, S.; Ristola, M.; Lundgren, J.; Grarup, J.; Kirk, O.
- Abstract
ATRIPLA is licensed for use only in HIV-positive persons whose viral loads <50 for ≥3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.
- Subjects
EUROPE; REVERSE transcriptase inhibitors; COMBINATION drug therapy; CONFIDENCE intervals; HIV infections; LONGITUDINAL method; MEDICAL cooperation; MEDICAL protocols; SCIENTIFIC observation; RESEARCH; RESEARCH funding; CROSS-sectional method; DESCRIPTIVE statistics; ODDS ratio; THERAPEUTICS
- Publication
Infection, 2014, Vol 42, Issue 4, p757
- ISSN
0300-8126
- Publication type
Report
- DOI
10.1007/s15010-014-0630-4